Presage Biosciences, a US-based developer of drugs for cancers in animals, has sold a minority stake worth $8m to peer Celgene.
Celgene is also investing an initial $5m to help pay for Presage’s clinical trials with more available if performance targets are hit.
Thomas Daniel, president of research and early development at Celgene, said: “Drug development is currently challenged by heavy reliance on in vitro test systems and animal xenografts of little relevance to individual patients.
“The Presage platform addresses…
